Hans Nissbrandt

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/11101574/hans-nissbrandt-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 papers	1,857 citations	24 h-index	29 g-index
29 ext. papers	2,025 ext. citations	4.6 avg, IF	4.33 L-index

#	Paper	IF	Citations
29	Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight. *Diabetes*, **2017**, 66, 1062-1073	0.9	48
28	GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. *Psychoneuroendocrinology*, **2016**, 65, 54-66	5	72
27	The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. *Neuropsychopharmacology*, **2016**, 41, 1199-209	8.7	45
26	Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. *Brain*, **2014**, 137, 1998-2014	11.2	139
25	Influence of ghrelin on the central serotonergic signaling system in mice. *Neuropharmacology*, **2014** , 79, 498-505	5.5	45
24	Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. *Physiology and Behavior*, **2014**, 136, 135-44	3.5	52
23	Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study. *BMC Medical Genetics*, **2014**, 15, 131	2.1	55
22	The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. *Journal of Neuroscience*, **2012**, 32, 4812-20	6.6	246
21	Noisy galvanic vestibular stimulation promotes GABA release in the substantia nigra and improves locomotion in hemiparkinsonian rats. *PLoS ONE*, **2012**, 7, e29308	3.7	40
20	Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. *Neurobiology of Disease*, **2011**, 42, 327-40	7.5	121
19	L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. *Journal of Neurochemistry*, **2010**, 112, 1465-76	6	206
18	PITX3 polymorphism is associated with early onset Parkinson's disease. *Neurobiology of Aging*, **2010** , 31, 114-7	5.6	57
17	Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors. *Experimental Neurology*, **2010**, 221, 251-9	5.7	9
16	Kinesin light chain 1 gene haplotypes in three conformational diseases. *NeuroMolecular Medicine*, **2010**, 12, 229-36	4.6	8
15	Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. *BMC Medical Genetics*, **2010**, 11, 36	2.1	86
14	Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. *Journal of Clinical Psychopharmacology*, **2008**, 28, 195-202	1.7	30
13	Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. *Neuropsychopharmacology*, **2007**, 32, 153-61	8.7	64

12	Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. *European Journal of Neuroscience*, **2006**, 24, 617-24	3.5	51
11	Dopamine Release in Substantia Nigra: Release Mechanisms and Physiological Function in Motor Control **2005**, 85-99		6
10	Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease **2005**, 133B, 88-92		60
9	Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. *Brain Research*, **2003**, 973, 81-91	3.7	62
8	Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. *Neuropsychopharmacology*, **1999**, 20, 287-96	8.7	52
7	Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by gamma-hydroxybutyric acid (GHBA) are specifically induced by activation of GABA(B) receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1998**, 357, 611-9	3.4	50
6	3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. *Journal of Neurochemistry*, **1997**, 69, 1684-92	6	19
5	Inhibition of dopamine re-uptake: significance for nigral dopamine neuron activity. *Synapse*, **1997**, 25, 215-26	2.4	16
4	Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. *Synapse*, **1994**, 17, 217-24	2.4	58
3	GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. *Synapse*, **1993**, 15, 229-38	2.4	89
2	gamma-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1993**, 348, 491-7	3.4	40
1	The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1992**, 346, 12-9	3.4	31